Study of a new immune cell therapy for young people with t-cell leukemia or lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an experimental immunotherapy (PA3-17) designed to target and kill cancer cells that carry the CD7 marker in children and teens with T-cell leukemia or lymphoma that has returned or is hard to treat. It aims to see if the treatment is safe and effective at the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 3 and 18 years old.
- Must have T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that has come back or not responded to standard treatment.
- Tumor cells must have a marker called CD7 (found on the cancer cells).
- Must be well enough to have an expected survival of at least 3 months, with adequate organ function (liver, kidneys, heart, and lungs).
- Must not have active central nervous system (brain or spinal cord) involvement, uncontrolled infections, or certain other serious medical conditions.
- Must not have received CAR-T or other gene-modified cell therapy before this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell therapy (CAR-T) that targets CD7, a protein found on T-cell leukemia and lymphoma cells. It is for people who have very small amounts of cancer remaining after a stem cell transplant.
This trial tests a new treatment called PA3-17, which uses your own immune cells modified to target and kill cancer cells that have a protein called CD7 on them. It is designed for patients with T-cell leukemia or lymphoma that has come back or did not respond to prior treatments.
This trial tests a new treatment called CD7 CAR-T for children with a high-risk type of blood cancer (T-cell leukemia or lymphoma). It aims to reduce the chance of the cancer coming back after initial treatment.
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
Hear when a new CD7+ T-ALL/LBL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.